The Knight Diagnostic Laboratories are CLIA-licensed and CAP-certified.  In addition, we adhere to all GLP & GCP guidelines related to the conduct of clinical trials.  During the past decade, KDL Directors and staff have provided diagnostic support for clinical trials sponsored by the NIH and over a dozen pharmaceutical and biotechnology companies.  Our experience and expertise in the development and validation of new assays/companion diagnostics makes us an excellent partner in trials for personalized cancer care.  In addition, we have a collaborative agreement with that automates annotation of our clinical reports with clinical trial information tailored to a patient’s specific tumor mutations. 

Publications related to some of the clinical trials that have been supported by KDL personnel:

  1. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen C-J, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CDM, Silberman S, Dimitrijevic S, Fletcher JA. Kinase mutations and imatinib mesylate response in patients with metastatic gastrointestinal stromal tumor. J Clin Onc 21:4342-4349, 2003.
  2. McArthur GA, Demetri GD, Van Oosterom A, Heinrich MC, Debiec-RychterM, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Onc 23:866-873, 2005.
  3. HeinrichMC, McArthur GA, DemetriGD, JoensuuH, BonoP, HerrmanR, HirteH, ​CrestaS, KoslinDB, CorlessCL, DirnhoferS, van Oosterom A, NikolovaZ, DimitrijevicS, FletcherJA,  Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Onc 24:1195-203, 2006.
  4. Heinrich MC, Corless CL, Blanke CD, Demetri, GD, Joensuu H, Roberts PJ, Eisenberg B, von Mehren M, Fletcher CDM, Sandau K, McDougall K, Ou WB, Chen C-J, Fletcher JA. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Onc 24:4764-74, 2006.
  5. Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, Soulieres D, Dirnhofer S, Harlow A, Town A, McKinley A, Supple SG, Seymour J, Di Scala L, van Oosterom A, Herrmann R, Nikolova Z, McArthur AG; for the Imatinib Target Exploration Consortium Study B2225. Phase II, Open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Can Res 14:2717-2725, 2008.
  6. Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin C, Benjamin RS, Bramwell VH, Demetri GD, Bertagnolli MM, Fletcher JA. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 26(33):5360-7, 2008.
  7. Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 26(33):5352-9, 2008.
  8. Schittenhelm MM, Kollmannsberger C, Oechsle K, Harlow A, Morich J, Honecker F, Kurek R, Störkel S, Kanz L, Corless CL, Wong K-K, Bokemeyer C, Heinrich MC. Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. Mol Cancer Ther. 8:481-9, 2009.
  9. Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. J Clin Oncol. 2013 Jul 8.
  10. Dematteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, von Mehren M, McCarter MD, Norton J, Maki RG, Pisters PW, Demetri GD, Brennan MF, Owzar K. Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor: ACOSOG Z9000 (Alliance) Intergroup Phase 2 Trial. Ann Surg. 2013 Jul 15.

OHSU Knight Cancer Institute Cancer Clinical Trails

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More